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Abstract
Background: Hepatolithiasis is a calculus disease of the liver with no known cause that is relatively uncommon,
and is characterized by a refractory nature and high frequency of recurrence. Hepatolithiasis is one of the diseases
listed by the Ministry of Health, Labour and Welfare of Japan under Research on Intractable Diseases, and it requires
further research on the pathogenesis as well as the therapeutic strategy. It is also included in the clinical guidelines
for cholelithiasis of the Japanese Society of Gastroenterology, which suggest guiding principles for the treatment of
hepatolithiasis.
Methods: we performed questionnaire surveys of hepatolithiasis twice in 2010 and in 2012. Verification of the
evidence-based clinical practice guidelines a questionnaire survey of 22 facilities in 2010 and 25 facilities in 2012
across Japan that provided cooperation, which enabled us to assess 210 new cases over a two-year period.
Conclusions: Comparison with two surveys that have been carried out previously revealed the main factor
associated with hepatolithiasis was a history of biliary tract surgery, which was noted in the majority of cases. In
addition, there was an increase of patients in whom balloon endoscopy was performed using transduodenal
approach. This method is not included in the treatment options of the current clinical guidelines for cholelithiasis,
so there may be a need to take it into consideration when the guidelines are revised.
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Introduction
Hepatolithiasis occurs less frequently compared to other
stone diseases of the biliary tract, such as cholelithiasis
and choledocholithiasis. The nationwide, cross-sectioned
surveys in Japan demonstrates the incident of hepato-
lithiasis accounts for 1.3 % of all cholelithiasis cases in
1997 and about 0.6 % in 2006. Its pathology, including
the causes of calculus formation, is complex, and the
disease shows a refractory and recurrent nature. Ac-
cordingly, this disease has been studied as part of the
research projects on intractable diseases of the Minis-
try of Health, Labour and Welfare of Japan since
1978. In 2009, the clinical guidelines for cholelithiasis
edited by the Japanese Society of Gastroenterology
were published, which also cover the diagnosis and
treatment of hepatolithiasis [1].
Currently, hepatectomy, endoscopic mechanical litho-
tripsy, and shock wave lithotripsy are performed alone
or in combination for the treatment of hepatolithiasis,
but the indications for selecting these treatment
methods have not been established at present. In
addition, it is a characteristic of this disease that patients
frequently develop conditions such as bile duct dilata-
tion after undergoing biliary tract surgery, and many of
these patients encounter postoperative problems after
reconstruction. However, no clear therapeutic strategies
have been suggested for patients with a surgical history.
Furthermore, while the presence of bile duct stenosis
has been suggested as a cause of lithogenesis and recur-
rence, bile duct stenosis and regions of hepatic atrophy
are also viewed as sites from which bile duct cancer
arises. Thus, apart from being a risk factor for lithogen-
esis and recurrence, it is believed that monitoring sites
of stenosis is the key element during follow-up after
calculus removal.
In the present study, we asked various facilities across
Japan to participate in a questionnaire survey and
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evaluated the responses in order to investigate the recent
incidence, methods of diagnosis, and therapeutic ap-
proach to hepatolithiasis, with the aim of examining the
validity of the current clinical guidelines.
Methods
The present survey was conducted by sending ques-
tionnaires regarding new hepatolithiasis patients over
a two-year period to facilities associated with the
Japan Biliary Association or the Japanese Research
Committee on Intractable Hepatic and Biliary Diseases
supported by the Health and Labor Sciences Research
Grant (Research on Intractable Diseases) of the Ministry
of Health, Labour and Welfare of Japan.
The questionnaire required responses regarding new
patients encountered between 2010 and 2011. Similar
surveys have already been performed between 2006 and
2007 and between 2008 and 2009. In 2009, the clinical
guidelines for cholelithiasis edited by the Japanese So-
ciety of Gastroenterology were published, which also
cover the diagnosis and treatment of hepatolithiasis
[1], so two questionnaire surveys between 2008 and
2009, and between 2010 and 2011, were in principle
compared in this study. Participants were asked to
provide responses to the following six items: 1) the
number of cases, 2) the presence or absence of symp-
toms, 3) history of biliary tract surgery, 4) methods
of diagnosis, 5) therapeutic approach, and 6) progno-
sis and complications. The number of facilities that
provided responses was 22 in the survey between
2008 and 2009, and 25 in the survey between 2010
and 2011. To assess the changes of clinical features
of management of hepatolithiasis, the number of pa-
tients per facility, the presence and absence of symp-
toms, history of biliary tract surgery, diagnostic
modalities such as ultrasound and/or X-ray (US/XP),
computed tomography and/or magnetic resonance
cholangiopancreatography (CT/MRCP), drip infusion
cholangiography-CT and/or endoscopic retrograde
cholangiopancreatography and/or endoscopic ultra-
sound (DIC-CT/ERCP/EUS), treatment approaches
such as surgical or nonsurgical treatment or others,
and prognosis and complications were evaluated.
Results
Number of patients
The total number of patients and facilities in the first
and second surveys was 158 patients/ 22 facilities, and
210 patients/ 25 facilities, respectively. The number of
patients per facility in the first and second surveys was
7.2 and 8.4, respectively (Fig. 1). Thus, both of the total
number of patients and patients per facility were in-
creased in the second survey when compared to the first
survey.
Symptoms
In both the first and second surveys, patients presenting
with symptoms accounted for 68 % and 61 % of all cases,
whereas asymptomatic patients accounted for 32 % and
39 %, respectively (Fig. 2). In both surveys, patients with
symptoms were predominant.
History of biliary tract surgery
Patients with a history of surgical procedures on the
biliary tract accounted for 40 % in the first survey,
and increased to 61 % in the second survey (Fig. 3).
There was an increase of treatment for patients with
hepatolithiasis who had previously undergone biliary
surgery (data not shown).
Diagnosis
This question concerned the actual examination
methods that led to the diagnosis of hepatolithiasis. In
both of the first and second surveys, US/XP accounted
for approximately 34 ~ 36 %, CT/MRCP for approximately
44 ~ 45 %, and DIC-CT/ERCP/EUS for approximately
20 ~ 22 % (Fig. 4). No drastic changes of the diagnostic
methods were observed.
Treatment
We asked about selection of the therapeutic approach to
hepatolithiasis. Surgical treatment, including hepatec-
tomy, intraoperative biliary fiberscopy, laparoscopic
choledochotomy, choledochojejunostomy, and liver
transplantation, was performed for 16.1 % in the first
survey and 13.3 % in the second survey, so there was
a slight decreasing trend (Fig. 5). On the other hand,
nonsurgical treatment, including percutaneous transhepa-
tic cholangioscopy (PTCS), endoscopic transpapillary ther-
apy (endoscopic retrograde cholangiopancreatography:
ERCP, peroral cholangioscopy: POCS), extracorporeal
shock wave lithotripsy (ESWL), and pharmacotherapy was
Fig. 1 Number of cases
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53.5 % in the first survey, and 65.7 % in the second survey,
showing an increase over the two surveys (Fig. 5). As for
the endoscopic route, the percentage of patients treated
via the percutaneous and transpapillary approaches was
about the same in each survey. With the transpapillary/
transduodenal approach, however, there was a decrease in
the number of cases where lithodialysis was performed via
biliary endoscopy, whereas the number of cases of direct
calculus removal increased. Data for therapeutic ap-
proaches in the second survey were shown in Fig. 6. On
the other hand, the percentage of patients who were
followed up without undergoing calculus removal was
30.3 ~ 30.5 % (Fig. 5).
Prognosis and complications
We asked about recurrence and complications in the early
and late phases, including deaths. The complication rate
was 23.8 %, and 50 out of 210 patients developed complica-
tions as shown in Fig. 7. The most frequently reported
complication was recurrent calculi, followed by cholangitis,
liver abscess, and intrahepatic bile duct cancer, in this order.
It was reported that complications led to death in three pa-
tients including cholangitis and postoperative death (1.4 %).
Discussion
The objectives of this survey were to examine the trend
in the number of patients with hepatolithiasis, assess
changes in the therapeutic approach, and confirm the
validity of the clinical guidelines of the Japanese Society
of Gastroenterology regarding hepatolithiasis.
Hepatolithiasis has been recognized as an intractable
disease since the Research Committee on Intrahepatic
Bile Duct Disorders was organized in 1978. This com-
mittee is currently known as the Research Committee
on Intractable Hepatic and Biliary Diseases, Subcommit-
tee on Hepatolithiasis, which is part of the Japanese
Ministry of Health, Labor and Welfare Research on In-
tractable Diseases. It continues to perform investigations
Fig. 2 Presence of symptoms
Fig. 3 History of biliary tract surgery
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and studies in order to determine the causes and clinical
features of hepatolithiasis, as well as to establish new
treatment methods. In the first nationwide survey
conducted by this study group, which collected cases
between 1975 and 1984, 4,381 patients (438 per year)
were reported during the 10-year period. The number
of cases in the last three surveys remains 210 over
2 years (105 per year), which suggests a decreasing
trend, although there were differences in the size of
the hospitals surveyed.
No significant changes were observed in the recent
methods used for the diagnosis of hepatolithiasis. How-
ever, we observed changes in the selection of treatment,
as new therapies were reported. When selecting the
treatment strategy for hepatolithiasis, the choice needs
to be based on 1) the composition of the calculi (i.e.,
cholesterol stones or calcium bilirubinate stones); 2) the
location of the calculi in order to choose an approach; 3)
the planned treatments including alleviation of bile duct
stenosis; 4) evaluation of liver atrophy and the extent of
liver resection; and 5) evaluation of intrahepatic bile
duct cancer. A therapeutic strategy is developed by also
taking into consideration various factors such as a history
of biliary tract surgery, in addition to the points men-
tioned above. According to the hepatolithiasis treatment
flow chart in the 2009 clinical guidelines for cholelithiasis
produced by the Japanese Society of Gastroenterology,
treatment selection should be based on the presence or
absence of a history of biliary tract surgery.
When we evaluated the present survey results, the per-
centage of postoperative cases showed an increase in the
third survey. In terms of treatment, there was a slight
decrease of surgical procedures and follow-up, while an
increase was observed in endoscopic procedures. This
Fig. 4 Diagnostic modalities
Fig. 5 Therapeutic approach
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trend might be due to a change in the management of
postoperative patients, for whom active procedures were
avoided in the past. It is likely that balloon endoscopy
has been applied clinically as a non-surgical treatment in
recent years, which made the transduodenal approach
possible in cases where postoperative biliary reconstruc-
tion is performed. The hepatolithiasis treatment flow-
chart in the cholelithiasis guidelines only recommends
PTCS when treating patients with a history of surgery
on the biliary tract [2–5]. Although it is also noted that
minimally invasive, repeatable treatment methods cen-
tering on PTCS can be selected in combination with
other procedures such as ESWL, the results of the
present survey have suggested the usefulness of trans-
duodenal procedures employing balloon endoscopy [6].
Given the clinical position of this method, we think that
revision of the guidelines is warranted, such as adding
this method to the flowchart.
In the present questionnaire survey, the responses to
the question regarding a history of biliary tract surgery
showed that 60 % of patients had a surgical history,
making up a majority of the subjects. In addition, there
was an increase in the number of cases where a transpa-
pillary or transduodenal approach was used, which was
likely to be the result of actively conducting calculus re-
moval in patients with a surgical history. On the other
hand, the percentage of hepatolithiasis complicated by
intrahepatic bile duct cancer has been reported to be
4.0–12.5 % [7–13], and it has been pointed out that the
risk of developing cholangiocarcinoma after removal of
calculi is increased by the presence of bile duct stenosis
[14]. In the study reports from the Health and Labor Sci-
ences Research Grant (Research on Intractable Diseases)
Research Committee on Hepatolithiasis (Atomi group) be-
tween 2005 and 2007, two factors that reduced the risk of
bile duct cancer were hepatectomy and administration of
UDCA. The fact that there has been an increase in the
number of patients undergoing endoscopic removal of cal-
culi suggests that there will be a need for careful follow-
Fig. 6 Trends of therapeutic approach (2010–2011)
Fig. 7 Prognosis and complications (2010–2011)
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up, since the bile ducts from which cancer arises are pre-
served. Furthermore, continued administration of UDCA
will be an essential requirement. When the cholelithiasis
guidelines are revised, due consideration of these issues
will be required.
Hepatolithiasis has been considered to be endemic in
East Asia, but is occasionally observed in Western coun-
tries, especially in those who have lived in the Orient
[15]. Since intrahepatic brown stones are pigment stones
consisting of bilirubin and cholesterol, biliary infection
with bile duct stricture and cholesterol metabolism dis-
orders are considered to be causative factors. However,
the present data of increased cases with a history of
biliary surgery suggest considerable changes in the
pathogenesis. Thus, it is recommended to pay attention to
screening hepatolithiasis using diagnostic modalities dem-
onstrated in guidelines through a follow-up of subjects
after biliary surgery, world-widely.
In conclusion, our three questionnaire surveys have re-
vealed that there has been an increase of hepatolithiasis
patients with a history of surgical procedures on the
biliary tract. In addition, an increasing number of
these patients are undergoing calculus removal via the
transduodenal approach with a balloon endoscope.
Because the risk of bile duct cancer is increased due
to preservation of the hepatic parenchyma and biliary
tree, the need for follow-up or continuation of UDCA
administration is expected. When the clinical guidelines
for cholelithiasis are revised, the creation of a flow chart
that takes these issues into account is desired.
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